Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluvastatin and Celebrex for Relapsed/Refractory Gliomas in Children and Young Adults
NCT02115074Phase 1Completed
- Sponsor
- Centre Oscar Lambret
- Start
- Jun 2014
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluvastatin in glioma, sponsored by Centre Oscar Lambret. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jun 2014; status: completed.
02
Drugs
fluvastatin
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02115074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02115074.